Pharmacological Modulation of Fluoropyrimidines

作者: Owen A. O’Connor

DOI: 10.1385/1-59259-864-1:133

关键词:

摘要: Few drugs in the present pharmacopia of antineoplastic pharmacology have exemplified importance bench-to-bed paradigm that has become cornerstone present-day developmental chemotherapy. From its rational synthesis by Heidelberger 1957 (1) to quantification molecular determinants fluorinated pyrimidine (fluoropyrimidine) activity, our understanding fluoropyrimidine helped mold concepts everything from target-oriented drug development phenotyping, and resistance synergy. It is thorough biochemical 5-fluorouracil (5-FU) we learned how exploit this biochemistry improve cytotoxicity 5-FU. Regrettably, although augmented improved overall response rates time disease progression parameters select clinical trials, it infrequently results survival—the end-point probably matters most. Pharmacological modulation any revolves around those critical relationships between targets cell, can their underlying biology a way renders combination agents complementary. Over past 45 yr, tomes been written on virtually every aspect with regard fluoropyrimidines. I will not reiterate details experience. Rather, chapter, briefly review historical experience order provide context for formulation new approaches. Unquestionably, however, future innovations use fluoropyrimidines, or other class matter, be markedly essential elements drug’s pharmacology.

参考文章(170)
A. F. Sobrero, C. Aschele, A. P. Guglielmi, A. M. Mori, G. G. Melioli, R. Rosso, J. R. Bertino, Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. Journal of the National Cancer Institute. ,vol. 85, pp. 1937- 1944 ,(1993) , 10.1093/JNCI/85.23.1937
C.D. Blanke, J. Shultz, J. Cox, M. Modiano, R. Isaacs, B. Kasimis, R. Schilsky, J. Fleagle, M. Moore, N. Kemeny, D. Carlin, L. Hammershaimb, D. Haller, A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer Annals of Oncology. ,vol. 13, pp. 87- 91 ,(2002) , 10.1093/ANNONC/MDF043
MM Borner, Monica Castiglione, M Bacchi, Walter Weber, R Herrmann, MF Fey, O Pagani, S Leyvraz, R Morant, B Pestalozzi, S Hanselmann, A Goldhirsch, Swiss Group for Clinical Cancer Research (SAKK, The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial Annals of Oncology. ,vol. 9, pp. 535- 541 ,(1998) , 10.1023/A:1008270916325
Y. Takebayashi, K. Yamada, K. Miyadera, T. Sumizawa, T. Furukawa, F. Kinoshita, D. Aoki, H. Okumura, Y. Yamada, S.-I. Akiyama, T. Aikou, The activity and expression of thymidine phosphorylase in human solid tumours European Journal of Cancer. ,vol. 32, pp. 1227- 1232 ,(1996) , 10.1016/0959-8049(96)00061-5
R. M. Hansen, L. Ryan, T. Anderson, B. Krzywda, E. Quebbeman, A. Benson, D. G. Haller, D. C. Tormey, Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer Journal of the National Cancer Institute. ,vol. 88, pp. 668- 674 ,(1996) , 10.1093/JNCI/88.10.668
Tomoyuki Sumizawa, Tatsuhiko Furukawa, Misako Haraguchi, Akihiko Yoshimura, Akira Takeyasu, Minoru Ishizawa, Yuji Yamada, Shin-ichi Akiyama, Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. Journal of Biochemistry. ,vol. 114, pp. 9- 14 ,(1993) , 10.1093/OXFORDJOURNALS.JBCHEM.A124146
Donna Boarman, Sydelle Zinn, Edward Chu, Carmen J. Allegra, Interaction of γ Interferon and 5-Fluorouracil in the H630 Human Colon Carcinoma Cell Line Cancer Research. ,vol. 50, pp. 5834- 5840 ,(1990)
Tracy Amsrud, Val G. Phares, Patrick A. Forler, Victor Chen, Krishna Menon, Chuan Shih, Beverly A. Teicher, Treatment Regimens Including the Multitargeted Antifolate LY231514 in Human Tumor Xenografts Clinical Cancer Research. ,vol. 6, pp. 1016- 1023 ,(2000)
Juan Wang, Sheng-Fang Su, Mark J. Dresser, Marci E. Schaner, Carla B. Washington, Kathleen M. Giacomini, Na+-dependent purine nucleoside transporter from human kidney: cloning and functional characterization American Journal of Physiology-renal Physiology. ,vol. 273, ,(1997) , 10.1152/AJPRENAL.1997.273.6.F1058
C G Leichman, T R Fleming, F M Muggia, C M Tangen, B Ardalan, J H Doroshow, F J Meyers, R F Holcombe, G R Weiss, A Mangalik, Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. Journal of Clinical Oncology. ,vol. 13, pp. 1303- 1311 ,(1995) , 10.1200/JCO.1995.13.6.1303